BioXcel Therapeutics – Developing Drugs in Neuroscience and Immuno-Oncology
Dr. Robert Risinger, Chief Medical Officer, Neuroscience at BioXcel Therapeutics, a biopharmaceutical company that uses artificial intelligence (AI) to identify drug targets and develop drugs in neuroscience and immuno-oncology, discusses the company’s lead product, IGALMI™ (dexmedetomidine), a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder and three more compounds in earlier phases of development: BXCL501, BXCL502, and +BXCL501.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Risinger has extensive experience leading clinical development from first in human through Phase 1-4 clinical trials to create a successful commercial product. His expertise includes designing and executing high quality translational studies within Phase 1 and 2 that provide insight and rapidly navigate development to successful registration trials. Prior to joining BioXcel Therapeutics, Dr. Risinger served as Vice President of Clinical Development at NeuroRx Pharmaceuticals and Senior Medical Director, Clinical Development, at Alkermes. In addition, he held roles of increasing responsibility at Bristol Myers Squibb, Ortho-McNeill Janssen Medical Affairs, and Johnson & Johnson. Dr. Risinger also served as Assistant Professor of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin, and as Staff Psychiatrist as a Major in the U.S. Air Force. He has a B.S. in Chemistry and Biology from Allegheny College and M.D. from the University of Pittsburgh School of Medicine.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
